Association between tumor necrosis factor-α ( TNF-α ) promoter −308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis

Zhen Zeng,Zhenhua Duan,Tianchen Zhang,Sheng Wang,Guixing Li,Jing Gao,Dongqing Ye,Shengqian Xu,Jianhua Xu,Li Zhang,Faming Pan
DOI: https://doi.org/10.1007/s10165-012-0699-5
2012-01-01
Abstract:Objectives Tumor necrosis factor ( TNF )- α promoter −308G/A polymorphism has been shown to be associated with high TNF-α production and poor response to anti-TNF-α treatment. However, not all patients show a good response to TNF-α antagonists, so this association remains controversial. This study was designed to investigate whether TNF-α promoter −308 G/A polymorphism is associated with responsiveness to anti-TNF therapy in rheumatoid arthritis (RA) patients. The 28-joint count Disease Activity Score (DAS) 28 or the American College of Rheumatology (ACR) improvement criteria 20 were used to measure patient response. Methods A meta-analysis was performed. Pooled ORs and 95 % CIs were calculated by both dominant and recessive genetic models. Results Fifteen studies with a total of 2127 patients were included in this meta-analysis. The results showed that patients with the G allele responded better to the treatment (OR = 1.87, 95 % CI 1.26–2.79). A subanalysis showed similar results. Conclusions Based on the results of this meta-analysis, RA patients with the TNF-α promoter −308 G allele respond better to TNF-α antagonist treatment, suggesting that this allele plays a major role in anti-TNF-alpha treatment response.
What problem does this paper attempt to address?